36389-16-9

Basic information

• Product Name: 5-FLUOROBENZOFUROXAN
• Synonyms: 5-FLUOROBENZOFUROXAN;5-fluorobenzofuroxan95+%;5-fluoro-1-oxido-2,1,3-benzoxadiazol-1-ium
• CAS NO: 36389-16-9
• Molecular Formula: C₆H₃FN₂O₂
• Molecular Weight: 154.1
• Mol File: 36389-16-9.mol
• Article Data: 5

Chemical Properties

• Melting Point: 49-50°C
• Boiling Point: 251.3±32.0 °C(Predicted)
• Appearance: /
• Density: 1.63±0.1 g/cm3(Predicted)
• PKA: 3.42±0.50(Predicted)
• CAS DataBase Reference: 5-FLUOROBENZOFUROXAN(CAS DataBase Reference)
• NIST Chemistry Reference: 5-FLUOROBENZOFUROXAN(36389-16-9)
• EPA Substance Registry System: 5-FLUOROBENZOFUROXAN(36389-16-9)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 36389-16-9(Hazardous Substances Data)

Upstream product

• 67312-96-3 1-azido-4-fluoro-2-nitrobenzene 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 448-39-5 N-(4-fluoro-2-nitrophenyl)acetamide 
• 371-40-4 4-fluoroaniline 
• 364-78-3 2-nitro-4-fluoroaniline 
• 351-83-7 4'-fluoroacetanilide 

Downstream Products

• 84044-35-9 6-Fluoro-2,3-dimethylquinoxaline 1,4-di-N-oxide 
• 149440-45-9 5-fluoro-2,1,3-benzoxadiazole 
• 1297593-81-7 2-benzoyl-3-(difluoromethyl)-7-fluoroquinoxaline 1,4-dioxide 
• 84044-37-1 6-Fluoro-2,3-bis(acetoxymethyl)quinoxaline 1,4-di-N-oxide 
• 84044-36-0 6-Fluoro-2,3-bis(bromomethyl)quinoxaline 1,4-di-N-oxide 
• 84044-38-2 6-Fluoro-2,3-bis(hydroxymethyl)quinoxaline 1,4-di-N-oxide 

Relevant articles and documents

Discovery of novel nitrogenous heterocyclic-containing quinoxaline-1,4-di-N-oxides as potent activator of autophagy in M.tb-infected macrophages

As a continuation of our research on antimycobacterial agents, a series of novel quinoxaline-1,4-di-N-oxides (QdNOs) containing various nitrogenous heterocyclic moieties at the R6 position were designed and synthesized. Antimycobacterial activities, as well as the cytotoxic effects, of the compounds were assayed. Four compounds (6b, 6f, 6n, and 6o), characterized by 2-carboxylate ethyl or benzyl ester, 6-imidazolyl or 1,2,4-triazolyl, and a 7-fluorine group, exhibited the most potent antimycobacterial activity against M.tb strain H37Rv (MIC ≤ 0.25 μg/mL) with low toxicity in VERO cells (SI = 169.3–412.1). Compound 6o also exhibited excellent antimycobacterial activity in an M.tb-infected macrophage model and was selected for further exploration of the mode of antimycobacterial action of QdNOs. The results showed that compound 6o was capable of disrupting membrane integrity and disturbing energy homeostasis in M.tb. Furthermore, compound 6o noticeably increased cellular ROS levels and, subsequently, induced autophagy in M.tb-infected macrophages, possibly indicating the pathways of QdNOs-mediated inhibition of intracellular M.tb replication. The in vivo pharmacokinetic (PK) profiles indicated that compounds 6o was acceptably safe and possesses favorable PK properties. Altogether, these findings suggest that compound 6o is a promising antimycobacterial candidate for further research.

Synthesis of novel fluorobenzofuroxans by oxidation of anilines and thermal cyclization of arylazides

The synthesis of several fluorobenzofuroxans by oxidation of fluoroanilines and thermal cyclization of fluoroarylazides is presented. The fluorobenzofuroxans prepared in this study presented tautomerism as evidenced by their NMR data. Benzofuroxans in general have biological activity and are synthetic intermediates for the preparation of several compounds with important pharmaceutical applications.

Potential antileukemic and immunosuppressive drugs. 3. Effects of homocyclic ring substitution on the in vitro drug activity of 4-nitrobenzo-2,1,3-oxadiazoles (4-nitrobenzofurazans) and their N-oxides (4-nitrobenzofuroxans).

-